Viendo 1-6 de 8 resultados.
Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical
13 de Octubre 2023
Background: This “Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association Clinical Practice Statement 2022” is intended to provide clinicians an overview of Food and Drug Administration (FDA) approved anti-obesity medications and investigational anti-obesity agents in development. Methods: The scientific information for this Clinical Practice Statement (CPS) is based upon published scientific citations, clinical perspectives of OMA authors, and peer revie
Leer mas
Nutrition and physical activity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2
13 de Octubre 2023
Background: This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) on Nutrition and Physical Activity provides clinicians an overview of nutrition and physical activity principles applicable to the care of patients with increased body fat, especially those with adverse fat mass and adiposopathic metabolic consequences. Methods: The scientific information and clinical guidance is based upon referenced evidence and derived from the clinical perspectives of the authors. Results:
Leer mas
Thirty Obesity Myths, Misunderstandings, and/or Oversimplifications: An Obesity Medicine Association
13 de Octubre 2023
Background: This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians an overview of 30 common obesity myths, misunderstandings, and/or oversimplifications. Methods: The scientific support for this CPS is based upon published citations, clinical perspectives of OMA authors, and peer review by the Obesity Medicine Association leadership. Results: This CPS discusses 30 common obesity myths, misunderstandings, and/or oversimplifications, utilizing
Leer mas
La obesidad: aspectos fisiopatológicos y clínicos
09 de Octubre 2023
Resumen | La obesidad es una enfermedad crónica, recurrente, de etiología compleja caracterizada por un desequilibrio de energía debido a un estilo de vida sedentario, un consumo excesivo de energía, o ambos. Se desarrolla a partir de la interacción de factores genéticos, sociales, conductuales, psicológicos, metabólicos, celulares y moleculares. Se define como la acumulación anormal o excesiva de tejido adiposo en relación co
Leer mas
Perceptions, Attitudes, and Barriers to Obesity Care in Mexico: Data From the ACTION-IO Study
09 de Octubre 2023
Objective: The Awareness, Care, and Treatment in Obesity Management–International Observation (ACTION-IO) study (ClinicalTrials.gov identifierNCT03584191) aimed to identify perceptions, attitudes, behaviors, andbarriers to effective obesity care in people with obesity (PwO) and healthcare professionals (HCPs). This study presents the results from Mexico.Methods: An online survey was conducted. In Mexico, eligible PwO were≥18 years of age with BMI ≥30 kg/m2 based on self-reported he
Leer mas
Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review
06 de Octubre 2023
As a chronic and relapsing disease, obesity negatiⓇvely impacts the health of men to a greater extent than that of women, with a higher risk of cardiovascular disease. Since lifestyle modifications alone are often challenging and limited for the maintenance of weight reduction, pharmacotherapy should be considered in a timely manner for obese men or overweight patients with weight-related comorbidities. Recent advances in anti-obesity drugs have enabled the potential of achieving clinically
Leer mas
